Lowenstein Sandler represented Timber Pharmaceuticals, Inc. (NYSE: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, as special corporate counsel in connection with Timber’s voluntary petition for relief under Chapter 11 of the Bankruptcy Code and the sale of all of Timber’s assets to Leo Pharma A/S. The Bankruptcy Court approved the sale on January 22, 2024, and the transaction closed the same day.
In 2020, Lowenstein represented the company formerly known as BioPharmX Corporation in the merger which formed the public company Timber Pharmaceuticals, Inc.
The Lowenstein deal team included Annie Nazarian Davydov, Steven Skolnick, Andrew E. Graw, Eric Jesse, Nicholas G. Mehler, Jeffrey D. Prol, Michael Walutes, Sarah Cole, Philip J. Gross, James C. Shehan, Deangeor Chin, Donna Calia, Brittany Clark, Crystal McDonald, and Amani Taha.
About Lowenstein Sandler LLP
Lowenstein Sandler is a national law firm with over 350 lawyers based in New York, Palo Alto, New Jersey, Utah, and Washington, D.C. The firm represents leaders in virtually every sector of the global economy, with particular emphasis on investment funds, life sciences, and technology. Recognized for its entrepreneurial spirit and high standard of client service, the firm is committed to the interests of its clients, colleagues, and communities.